Acotec Scientific Holdings Limited (6669.HK)
- Previous Close
6.480 - Open
6.380 - Bid 6.250 x --
- Ask 6.350 x --
- Day's Range
6.230 - 6.800 - 52 Week Range
5.800 - 17.000 - Volume
286,000 - Avg. Volume
249,320 - Market Cap (intraday)
1.962B - Beta (5Y Monthly) 0.09
- PE Ratio (TTM)
125.20 - EPS (TTM)
0.050 - Earnings Date Mar 25, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
17.11
Acotec Scientific Holdings Limited operates as an interventional medical device company that offers vascular interventional treatment products in Mainland China, Europe, and internationally. The company's products include AcoArt Orchid & Dhalia, a paclitaxel DCB used to prevent stenosis or occlusion in superficial femoral artery (SFA) and popliteal artery (PPA) for the treatment of lower extremity artery disease (LEAD) with a vascular interventional approach; and AcoArt Tulip & Litos, a paclitaxel coated DCB used to prevent stenosis or occlusion in below-theknee (BTK) arteries for the treatment of chronic limb-threatening ischemia with a vascular interventional approach. It also offers devices targeting vascular surgery, including AcoArt Iris & Jasmin; AcoArt Lily & Rosmarin; Peripheral Aspiration System (AcoStream); Radiofrequency Ablation System (AcoArt Cedar); Peripheral Support Catheter (Vericor); The PTA Balloon (P-Conic); and 2nd Gen Peripheral Aspiration System (2nd Generation AcoStream). In addition, its devices targeting cardiology include Semi-compliant PTCA Balloon (YAN), Coronary CTO Recanalization Balloon (RT-Zero), and Coronary CTO Antegrade Micro-Catheter (Vericor-14); devices targeting nephrology include Paclitaxel Coated High-Pressure Balloon (ACOART AVENS) and AV Scoring Balloon (Peridge); devices targeting neurology comprise Intracranial PTA Balloon (NEO-Skater); and devices targeting andrology include AcoArt Orchid & Dhalia and AcoArt Tulip & Litos. Further, the company trades procedural medical devices. The company was incorporated in 2020 and is headquartered in Beijing, China. Acotec Scientific Holdings Limited operates as a subsidiary of Boston Scientific Group plc.
www.acotec.cnRecent News: 6669.HK
Performance Overview: 6669.HK
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6669.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6669.HK
Valuation Measures
Market Cap
2.03B
Enterprise Value
1.33B
Trailing P/E
119.87
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.81
Price/Book (mrq)
1.45
Enterprise Value/Revenue
2.81
Enterprise Value/EBITDA
18.90
Financial Highlights
Profitability and Income Statement
Profit Margin
3.06%
Return on Assets (ttm)
0.47%
Return on Equity (ttm)
1.13%
Revenue (ttm)
473.85M
Net Income Avi to Common (ttm)
14.49M
Diluted EPS (ttm)
0.050
Balance Sheet and Cash Flow
Total Cash (mrq)
879.21M
Total Debt/Equity (mrq)
18.05%
Levered Free Cash Flow (ttm)
--
Research Analysis: 6669.HK
Analyst Price Targets
Fair Value
No Fair Value available for this ticker
Company Insights: 6669.HK
6669.HK does not have Company Insights